Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

Université de Sherbrooke

$46,000.00

Biomimetic materials and bioprocesses for high-density culture of cells and organs

FY 2024-25

Summary
The regenerative medicine market, estimated at USD 55 billion in 2022, is projected to grow. Chimeric Antigen Receptor (CAR) Tcells and Tumor Infiltrating Lymphocytes (TILs) have highlighted the potential to industrialize personalized medical cellular therapies, opening the door to a next revolution, the manufacture of engineered tissue products. This creates opportunities for the development of bioprocesses to support and market tissue-based products. More than 4 million Canadians lives with diabetes, costing $30 billion. Pancreatic islet transplantation can restore the required mass of functional beta cells to treat type 1 diabetics. Improving the success of islet transplantation is important. In addition, in Canada each year, more than three million people suffer from liver diseases and around 5,000 are dying due to liver diseases. Tissue engineering has been applied to embed and cultivate cells and tissues in scaffolds made of biomaterials, using bioreactors. The aim is to expose cells and organs to environments mimicking their native ones, so they can behave physiologically. Decellularized organs and tissues (referred to as ExtraCellular Matrix (ECM)) can serve as scaffolds for cell therapies. However, little is known about mechanisms governing the effects on cells of ECM produced by organ decellularization. LONG-TERM OBJECTIVE: to develop biomaterials, devices, and automated bioprocesses to isolate and expand viable and functional cells and tissues at high density. SPECIFIC OBJECTIVES are to develop, characterize and validate: 1) A perfusion reactor for organ decellularization and cell/tissue culture; 2) ECM-based scaffolds to study pancreatic cells and islets; 3) ECM-based scaffolds to study hepatic cells and tissue; 4) Decellularized blood vessels as perfusion scaffolds for vascular grafting of cells and tissues. ANTICIPATED SIGNIFICANCE AND NOVELTY: 1) Despite their importance, not enough is known about the interactions of ECM components and cells and tissues. Our ECM-based biomaterials allow studying cell responses. 2) Knowing how biomimetic scaffolds affect cells and tissues, in this case pancreatic and hepatic systems, will support development of improved cell therapies. 3) Understanding how fluid flow conditions affect cells and tissues is essential to identify how transplanted cells and tissues are affected at an implantation site. Our perfusion bioreactor is one of the few allowing carrying out such studies. Developing an automated process will allow transfering manually operated laboratory-scale methods into industrial processes for cell therapy products. 4) Fluid circulation in any bulk tissue is mandatory to sustain cell survival and function, and the proposed device is a potential solution. This research will result in key scientific papers and patents creating knowledge and yielding technology transfer. It contributes to train highly qualified personnel.
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2024-06065
Name nom
Vermette, Patrick
Department département
Département de génie chimique et de génie biotechnologique
Organization id
68
Institution établissement
Université de Sherbrooke
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
46000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Biomimetic materials and bioprocesses for high-density culture of cells and organs
Keywords
biomaterials; tissue engineering; tissue and organ decellularization; extracellular matrix (ecm)-based biomaterials; perfusion bioreactor; bioglue for cell grafting; 3d cell culture; pancreatic cells and islets; hepatic cells and tissue; medical devices
Application summary
The regenerative medicine market, estimated at USD 55 billion in 2022, is projected to grow. Chimeric Antigen Receptor (CAR) Tcells and Tumor Infiltrating Lymphocytes (TILs) have highlighted the potential to industrialize personalized medical cellular therapies, opening the door to a next revolution, the manufacture of engineered tissue products. This creates opportunities for the development of bioprocesses to support and market tissue-based products. More than 4 million Canadians lives with diabetes, costing $30 billion. Pancreatic islet transplantation can restore the required mass of functional beta cells to treat type 1 diabetics. Improving the success of islet transplantation is important. In addition, in Canada each year, more than three million people suffer from liver diseases and around 5,000 are dying due to liver diseases. Tissue engineering has been applied to embed and cultivate cells and tissues in scaffolds made of biomaterials, using bioreactors. The aim is to expose cells and organs to environments mimicking their native ones, so they can behave physiologically. Decellularized organs and tissues (referred to as ExtraCellular Matrix (ECM)) can serve as scaffolds for cell therapies. However, little is known about mechanisms governing the effects on cells of ECM produced by organ decellularization. LONG-TERM OBJECTIVE: to develop biomaterials, devices, and automated bioprocesses to isolate and expand viable and functional cells and tissues at high density. SPECIFIC OBJECTIVES are to develop, characterize and validate: 1) A perfusion reactor for organ decellularization and cell/tissue culture; 2) ECM-based scaffolds to study pancreatic cells and islets; 3) ECM-based scaffolds to study hepatic cells and tissue; 4) Decellularized blood vessels as perfusion scaffolds for vascular grafting of cells and tissues. ANTICIPATED SIGNIFICANCE AND NOVELTY: 1) Despite their importance, not enough is known about the interactions of ECM components and cells and tissues. Our ECM-based biomaterials allow studying cell responses. 2) Knowing how biomimetic scaffolds affect cells and tissues, in this case pancreatic and hepatic systems, will support development of improved cell therapies. 3) Understanding how fluid flow conditions affect cells and tissues is essential to identify how transplanted cells and tissues are affected at an implantation site. Our perfusion bioreactor is one of the few allowing carrying out such studies. Developing an automated process will allow transfering manually operated laboratory-scale methods into industrial processes for cell therapy products. 4) Fluid circulation in any bulk tissue is mandatory to sustain cell survival and function, and the proposed device is a potential solution. This research will result in key scientific papers and patents creating knowledge and yielding technology transfer. It contributes to train highly qualified personnel.